5.12
price down icon1.92%   -0.08
 
loading
Pavmed Inc stock is traded at $5.12, with a volume of 14,260. It is down -1.92% in the last 24 hours and down -13.92% over the past month. PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$5.20
Open:
$5.2699
24h Volume:
14,260
Relative Volume:
0.53
Market Cap:
$35.65M
Revenue:
$85,000
Net Income/Loss:
$-22.16M
P/E Ratio:
-0.1359
EPS:
-37.672
Net Cash Flow:
$-6.29M
1W Performance:
+7.37%
1M Performance:
-13.92%
6M Performance:
-50.34%
1Y Performance:
-62.21%
1-Day Range:
Value
$4.75
$5.2699
1-Week Range:
Value
$4.19
$5.27
52-Week Range:
Value
$3.85
$28.44

Pavmed Inc Stock (PAVM) Company Profile

Name
Name
Pavmed Inc
Name
Phone
(212) 949-4319
Name
Address
360 MADISON AVENUE, NEW YORK, NY
Name
Employee
41
Name
Twitter
@PAVmedinc
Name
Next Earnings Date
2026-08-14
Name
Latest SEC Filings
Name
PAVM's Discussions on Twitter

Compare PAVM vs ABT, SYK, MDT, BSX, EW

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PAVM icon
PAVM
Pavmed Inc
4.98 37.23M 85,000 -22.16M -6.29M -37.67
ABT icon
ABT
Abbott Laboratories
110.08 192.51B 46.59B 5.41B 7.38B 3.0938
SYK icon
SYK
Stryker Corp
332.38 130.11B 25.27B 3.34B 4.57B 8.6334
MDT icon
MDT
Medtronic Plc
90.66 116.83B 36.36B 4.84B 5.43B 3.7261
BSX icon
BSX
Boston Scientific Corp
51.55 75.11B 20.62B 3.56B 3.48B 2.3847
EW icon
EW
Edwards Lifesciences Corp
90.78 52.80B 6.30B 1.07B 1.09B 1.8406

Pavmed Inc Stock (PAVM) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-30-21 Initiated Cantor Fitzgerald Overweight
Nov-05-20 Initiated Ascendiant Capital Markets Buy
Jun-28-18 Initiated Maxim Group Buy

Pavmed Inc Stock (PAVM) Latest News

pulisher
Aug 16, 2026

St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com

Aug 16, 2026
pulisher
Aug 15, 2026

PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria

Aug 15, 2026
pulisher
Aug 15, 2026

PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria

Aug 15, 2026
pulisher
Aug 15, 2026

PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang

Aug 15, 2026
pulisher
Aug 14, 2026

PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus

Aug 14, 2026
pulisher
Aug 14, 2026

Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 14, 2026
pulisher
Aug 14, 2026

PAVM Q2 FY2026 earnings call - finance.biggo.com

Aug 14, 2026
pulisher
Aug 14, 2026

PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus

Aug 14, 2026
pulisher
Aug 14, 2026

Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus

Aug 14, 2026
pulisher
Aug 14, 2026

Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026
pulisher
Aug 14, 2026

Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com

Aug 14, 2026
pulisher
Aug 14, 2026

PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga

Aug 14, 2026
pulisher
Aug 14, 2026

Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire

Aug 14, 2026
pulisher
Aug 14, 2026

PAVmed Q2 2026 Earnings Call Transcript - marketbeat.com

Aug 14, 2026
pulisher
Aug 13, 2026

PAVmed Inc. (PAVM) investor discloses 8.8% stake and trust holdings - Stock Titan

Aug 13, 2026
pulisher
Aug 13, 2026

PAVmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses - Quiver Quantitative

Aug 13, 2026
pulisher
Aug 13, 2026

PAVmed Inc. 2026: Revenue $33K, EPS ($0.87) — 10-Q Summary - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget

Aug 13, 2026
pulisher
Aug 13, 2026

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire

Aug 13, 2026
pulisher
Aug 12, 2026

Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan

Aug 12, 2026
pulisher
Aug 11, 2026

PAVmed Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView

Aug 11, 2026
pulisher
Aug 07, 2026

PAVmed Inc (NASDAQ: PAVM) Share Price, PAVM Stock News, PAVM Share Price & Updates - Kalkine

Aug 07, 2026
pulisher
Aug 07, 2026

PAVM Q2'26 Earnings: revenue estimate is 48.00K USD - TradingView

Aug 07, 2026
pulisher
Aug 05, 2026

Lucid Diagnostics Secures Commercial Coverage - Moomoo

Aug 05, 2026
pulisher
Aug 05, 2026

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar

Aug 05, 2026
pulisher
Aug 05, 2026

PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard test - Bitget

Aug 05, 2026
pulisher
Aug 05, 2026

P&F Products & Features GmbH Announces Acquisition of AVVie GmbH - AOL.com

Aug 05, 2026
pulisher
Aug 05, 2026

Lucid's EsoGuard Is the Only Esophageal Precancer Test Meeting Coverage Criteria - Stock Titan

Aug 05, 2026
pulisher
Aug 04, 2026

Lucid Diagnostics to Participate in Upcoming Investor Conferences - Morningstar

Aug 04, 2026
pulisher
Aug 04, 2026

Academic Orthopaedic Consortium Launches POST™, the First National Digital Platform Connecting MedTech, Pharma, and Academic Orthopaedic Departments - AOL.com

Aug 04, 2026
pulisher
Aug 04, 2026

Lucid Diagnostics Sets Boston Fireside Chat and Virtual Meetings - Stock Titan

Aug 04, 2026
pulisher
Aug 03, 2026

Weekly Recap: Q2 2026 earnings call and EsoGuard/EsoCheck sales - TradingView

Aug 03, 2026
pulisher
Aug 03, 2026

PAVmed Inc. (PAVM) Climbs 4.42% to $5.24 as Bullish Momentum BuildsGap Up Stocks - dars.gov.et

Aug 03, 2026
pulisher
Jul 31, 2026

PAVmed CEO to update operations; CFO to discuss Q2 financial results Aug. 14 - Stock Titan

Jul 31, 2026
pulisher
Jul 30, 2026

PAVmed to Host Business Update Conference Call on August 14 - Intellectia AI

Jul 30, 2026
pulisher
Jul 30, 2026

PAVMED Q1 2026 Earnings: EPS Shock Sinks Shares as Revenue Remains UnreportedEarnings Surprise Stocks - dars.gov.et

Jul 30, 2026
pulisher
Jul 27, 2026

PAVmed Inc (PAVM) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

PAVmed Inc (PAVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

PAVmed Inc (PAVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 27, 2026

Pavmed Inc Stock (PAVM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
ZBH ZBH
$98.38
price down icon 2.25%
STE STE
$230.07
price down icon 1.27%
PHG PHG
$26.77
price down icon 1.85%
$72.20
price down icon 2.06%
$88.44
price down icon 1.44%
EW EW
$90.81
price down icon 0.83%
Cap:     |  Volume (24h):